GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - TANGO THERAPEUTICS INC

Financial Performance:

• No specific financial metrics (revenue, earnings, cash flow, debt) were disclosed in this transcript as Tango Therapeutics is a pre-revenue, clinical-stage biotech company focused on drug development rather than commercial sales.

Guidance and Future Outlook:

• Plan to initiate a Phase 3 frontline study for pancreatic cancer in the first half of 2025.
• Regulatory strategy for both frontline and second-line pancreatic cancer, as well as non-small cell lung cancer (NSCLC), to be finalized and announced.
• Data update regarding the second PMT5 inhibitor (TNG456) in NSCLC expected in January 2027 (note: transcript mentions "January" following 2024 context, likely implying Jan 2025 or early 2026 depending on current date, but transcript text says "beginning of 27").
• Goal to determine the specific indication strategy for TNG456 (NSCLC) versus Vopixomedastat (Pancreatic) based on upcoming data.
• Priority to engage with the FDA regarding accelerated approval pathways for the second-line pancreatic cancer setting before the end of the year.

Business Segments and Product Lines:

• Vopixomedastat (PM5 inhibitor): Identified as the ideal candidate for pancreatic cancer due to high potency and inability to cross the blood-brain barrier (BBB), which is beneficial for avoiding CNS toxicity in this population.
• TNG456 (PM5 inhibitor): Designed to cross the BBB, making it the preferred candidate for NSCLC where 30-50% of patients have brain metastases.
• Daxan-Rasip: Combination arm showing 82% response rate in 22 pancreatic cancer patients and 81% combined response rate with NSCLC patients; durable responses with 88% PFS rate at 9 months.
• Zoldan-Rasip: Combination arm showing lower response rates compared to Daxan-Rasip; hypothesized due to less effective targeting of the Ras-RAF component.
• Eraska Collaboration: First-in-human study initiated for Eraska 0015 combined with Vopixomedastat; comprehensive development plan under discussion.
• Glioblastoma: Investigating TNG456 in relapsed/refractory patients; potential to move to adjuvant setting if data is sufficiently attractive.

Market and Competitive Landscape:

• Positioning Vopixomedastat as the "best" PM5 inhibitor with superior safety, tolerability, and combinability profiles compared to competitors.
• Belief that differentiation in the PM5 inhibitor space will emerge based on safety profiles and combination potential rather than raw efficacy.
• Acknowledged competition from other companies developing PanRAS and PM5 inhibitor combinations (e.g., Contemplate), but confident in Tango's early-mover advantage in clinical confirmation of synergy.
• Strong partnership and reputation with the FDA, facilitating smooth trial design discussions.

Risks and Challenges:

• Supply Chain: No definitive supply agreement with Revolution Medicines (RevMed) for the Phase 3 frontline study as of the call; negotiations ongoing but Tango is prepared to execute the study without RevMed support if necessary.
• Regulatory Pathways: Uncertainty remains regarding the FDA's stance on demonstrating the contribution of individual components for a combination drug approval in the second-line setting.
• Clinical Execution: Operational complexity in launching large Phase 3 trials; reliance on operational readiness for study startup.
• Drug Development Failure: Standard risk that preclinical synergy may not translate or that safety profiles may worsen in larger trials, though current data suggests high confidence.

Management Commentary and Tone:

• CEO Malte Peters described the company as a "late-stage drug development, pre-approval, pre-commercial organization" with a laser-sharp focus on execution.
• Tone was highly confident and optimistic, emphasizing the significance of the clinical data and the speed of advancement.
• Management expressed strong conviction in the mechanistic synergy of their combination therapies and their ability to navigate regulatory hurdles efficiently.

Analyst Questions and Answers:

• KRAS G12D Efficacy: Confirmed that while early data was limited, G12D patients have been enrolled in both combination arms; high synergy observed in G12R patients (50% response vs 7% with monotherapy) supports confidence in G12D results.
• Study Design: FDA feedback was supportive of the 1:1 randomized Phase 3 design with dual primary endpoints (Response Rate and PFS) and the proposed 240-patient-per-arm size.
• Dose Reductions: Mechanism confirmed where lowering Vopixomedastat dose also reduces exposure to Daxan-Rasip, simplifying toxicity management.
• RevMed Supply: Clarified that while RevMed collaboration is preferred, it is not a barrier to study initiation; operational readiness is the primary gating factor.

Other Key Points:

• Safety profile of the Daxan-Rasip-Vopixomedastat combination is highly favorable, with no Grade 3 rash or stomatitis/mucositis observed, attributed to the counterbalancing mechanism of phospho-ERK regulation in the skin.
• The company has transitioned from a discovery organization (2018) to a mature late-stage development entity, adding significant expertise to the team.
• Three key milestones identified for the next 12 months: Initiation of the frontline Phase 3 study, finalization of the regulatory strategy, and clarification of the NSCLC development path.